Skip to main content

Table 2 Adjusted risk of breast cancer-specific mortality at weekly points of TTS by subtype

From: Surgical delay-associated mortality risk varies by subtype in loco-regional breast cancer patients in SEER-Medicare

 

HR + /HER2-

HER2 + 

HR-/HER2-

sHR

95% CI

sHR

95% CI

sHR

95% CI

TTS (days)

14

1.15

(0.99–1.31)

1.06

(0.79–1.42)

1.07

(0.85–1.34)

21

1.05

(0.97–1.13)

0.97

(0.84–1.13)

1.00

(0.89–1.13)

28

1.00

(0.99–1.02)

0.99

(0.96–1.02)

1.00

(0.98–1.02)

35

1.00

(0.97–1.03)

1.04

(0.97–1.12)

1.01

(0.96–1.07)

42

1.03

(0.96–1.11)

1.11

(0.96–1.28)

1.04

(0.93–1.16)

49

1.08

(0.98–1.19)

1.2

(0.98–1.46)

1.07

(0.92–1.25)

56

1.15

(1.02–1.29)

1.28

(1.02–1.64)

1.11

(0.91–1.34)

63

1.24

(1.08–1.42)

1.38

(1.02–1.87)

1.14

(0.91–1.44)

70

1.36

(1.16–1.59)

1.48

(1.02–2.13)

1.18

(0.89–1.56)

77

1.49

(1.25–1.80)

1.59

(1.00–2.51)

1.22

(0.86–1.72)

84

1.64

(1.32–2.02)

1.69

(0.97–2.94)

1.26

(0.83–1.90)

91

1.83

(1.42–2.37)

1.8

(0.92–3.53)

1.30

(0.79–2.14)

98

2.03

(1.50–2.74)

1.92

(0.85–4.35)

1.34

(0.73–2.45)

105

2.26

(1.59–3.22)

2.04

(0.78–5.35)

1.38

(0.68–2.82)

112

2.50

(1.67–3.78)

2.15

(0.71–6.51)

1.42

(0.63–3.21)

119

2.79

(1.75–4.45)

2.71

(0.64–8.06)

1.46

(0.58–3.71)

  1. Time points in this table at which the simultaneous 95% CI did not include a sHR of 1 in comparison to TTS=30 days are noted by bold font
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us